Private payday

How AbbVie found another pipeline in a product with Stemcentrx's Rova-T

AbbVie Inc. (NYSE:ABBV) is paying an eye-popping $5.8 billion up front and a potential $4 billion in milestones for privately held Stemcentrx Inc., but the pharma thinks the price is worth it to obtain another "pipeline in a product" like Imbruvica ibrutinib.

The driver of the deal is Stemcentrx's Rova-T rovalpituzumab tesirine. The antibody-drug conjugate (ADC)

Read the full 564 word article

User Sign In